Suzhou Medton Pharmaceutical Technology

Suzhou Medton Pharmaceutical Technology is a clinical-stage biotechnology company headquartered in Suzhou, China, specializing in the development of protein degradation therapies. The company utilizes its proprietary PROTAC (Proteolysis Targeting Chimera) and molecular glue platforms to create novel small molecule drugs for oncology and autoimmune indications. Its lead programs focus on degrading key disease-driving proteins such as Bruton's tyrosine kinase (BTK) and the androgen receptor. Medton aims to overcome drug resistance associated with traditional inhibitors by completely removing target proteins from cells. The company is backed by prominent venture capital firms and operates out of the Suzhou Industrial Park.